Cargando…
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
SIMPLE SUMMARY: Immunotherapy-based treatments have brought many new options in the treatment of multiple myeloma; still, the disease will inevitably relapse as it remains incurable. The development of non-immunologic drugs is therefore still needed, particularly for patients with advanced myeloma w...
Autores principales: | Bobin, Arthur, Gruchet, Cécile, Guidez, Stéphanie, Gardeney, Hélène, Nsiala Makunza, Laly, Vonfeld, Mathilde, Lévy, Anthony, Cailly, Laura, Sabirou, Florence, Systchenko, Thomas, Moya, Niels, Leleu, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534104/ https://www.ncbi.nlm.nih.gov/pubmed/34680358 http://dx.doi.org/10.3390/cancers13205210 |
Ejemplares similares
-
The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020) -
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
por: Bobin, Arthur, et al.
Publicado: (2020) -
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
por: Gardeney, Hélène, et al.
Publicado: (2020) -
Hairy cell leukemia with isolated bone lesions
por: Cailly, Laura, et al.
Publicado: (2023) -
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
por: Fouquet, Guillemette, et al.
Publicado: (2018)